Thomas Wynn
Company: Rgenta Therapeutics Inc.
Job title: Director - Medicinal Chemistry
Bio:
A medicinal chemist with over 20 years of experience in small molecule drug discovery in both pharmaceutical and biotech companies. I have extensive experience in the CNS, antibiotic, immunology, and oncology therapeutic areas.
Specialties: Small molecule drug design, structure based drug design, oncology, immunology, anti-infectives, CNS therapies, pro-drug design, in vivo pharmacology, managing scientists, managing external resources.
Seminars:
Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases 1:00 pm
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas • What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space • Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic…Read more
day: Conference Day One
Optimizing Chemical Matter Against RNA to Improve Therapeutics: Lessons from Rgenta’s RNA-Targeted Platform 4:15 pm
• Introducing Rgenta’s RNA-targeting small molecule platform and its approach to addressing disease-relevant RNA targets • Highlighting case studies from lead programs in ACC & Huntington’s disease to showcase platform-driven success in drug discovery • Sharing insights on generating and refining small molecules as RNA splice modulators, including strategies for modeling splice sitesRead more
day: Conference Day One